On 25 February 2019 the European Commission withdrew the marketing authorisation for Altargo (retapamulin) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Glaxo Group Ltd, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons. Altargo was granted marketing authorisation in the EU on 24 May 2007 for the short treatment of some superficial skin infections in adults and children from the age of 9 months. The marketing authorisation was initially valid for a 5\-year period. It was then granted unlimited validity in 2012\. The European Public Assessment Report (EPAR) for Altargo is updated accordingly to reflect the fact that the marketing authorisation is no longer valid.
Therapeutic Indication
Short term treatment of the following superficial skin infections: * impetigo; * infected small lacerations, abrasions or sutured wounds. See sections 4\.4 and 5\.1 for important information regarding the clinical activity of retapamulin against different types of *Staphylococcus aureus*. Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Therapeutic Area (MeSH)
ATC Code
D06AX13
ATC Item
N/A
Pharmacotherapeutic Group
Antibiotics and chemotherapeutics for dermatological use
Active Substance (Summary)
INN / Common Names
EMA Name
Altargo
Medicine Name
Altargo
Aliases
N/ANo risk management plan link.
